Orexigen Therapeutics (OREX) Reaches New 52-Week Low at $1.28

Orexigen Therapeutics, Inc. (NASDAQ:OREX) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $1.28 and last traded at $1.30, with a volume of 193900 shares. The stock had previously closed at $1.38.

Several equities research analysts have issued reports on the stock. ValuEngine cut shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of Orexigen Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th.

The company has a debt-to-equity ratio of -2.75, a quick ratio of 1.71 and a current ratio of 2.00.

Orexigen Therapeutics (NASDAQ:OREX) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.13) by $0.78. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The business had revenue of $18.90 million for the quarter, compared to analysts’ expectations of $24.20 million. During the same period last year, the company earned $1.12 earnings per share. The company’s quarterly revenue was up 170.0% on a year-over-year basis. equities research analysts expect that Orexigen Therapeutics, Inc. will post -10.08 EPS for the current year.

An institutional investor recently raised its position in Orexigen Therapeutics stock. Wells Fargo & Company MN increased its stake in Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 45,638 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Orexigen Therapeutics worth $132,000 as of its most recent SEC filing. Institutional investors own 34.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Orexigen Therapeutics (OREX) Reaches New 52-Week Low at $1.28” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.com-unik.info/2017/12/15/orexigen-therapeutics-orex-reaches-new-52-week-low-at-1-28.html.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

What are top analysts saying about Orexigen Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orexigen Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit